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Three areas of development in the surgical management of breast cancer received significant attention in 2003—
breast-conserving surgery, sentinel lymph node (SLN) biopsy, and ductal lavage. Provocative investigations focusing on these
controversial aspects of surgical care were presented at major national oncology meetings throughout the year. The recently pub-
lished 20-year updates by the National Surgical Adjuvant Breast and Bowel Project (NSABP) and the Italian National Cancer Insti-
tute confirm the survival equivalence of breast-conserving surgery and mastectomy in early stage disease. Data reveal, however,
that this strategy is underutilized in the United States when compared with other countries. A meta-analysis of close to 70 published
trials on the use of SLN biopsy has revealed an overall SLN identification rate of greater than 90%, with a false-negative rate of
8.4%. Two major controversies remain to be resolved: Is there a subset of sentinel node-positive patients who may safely avoid
complete axillary lymph node dissection? What is the best way integrate lymphatic mapping into neoadjuvant chemotherapy pro-
tocols? The strength of ductal lavage as a risk assessment adjunct is related to the ability to detect cellular atypia, a feature asso-







The National Surgical Adjuvant Breast and Bowel
Project (NSABP) and the Italian National Cancer Institute
recently published 2-year updates confirming the sur-
vival equivalence of breast-conserving therapy and mas-
tectomy as management for early stage breast cancer
(1,2). At the December 2002 San Antonio Breast Cancer
Symposium (SABCS) the National Cancer Institute (NCI)
in the United States presented additional long-term
survival data regarding the breast-conserving approach (3).
Poggi et al. (3) reported outcome data on 247 patients
with primary breast tumors up to 5 cm in size who were
randomized to lumpectomy with axillary lymph node
dissection (ALND) versus modified radical mastectomy.
With a median follow-up of 18 years, no difference in
overall survival was noted. This confirms, on a decidedly
long-term basis, the oncologic safety of breast-conserving
surgery in patients with T1 and T2 breast cancers. These
data also reaffirm a preexisting concept that distant relapse
from breast cancer and breast cancer mortality are primarily
consequences of underlying primary biology as opposed
to what is surgically done to the breast.
Despite the numerous studies attesting to the safety of
breast-conserving therapy, it is the aim of all breast sur-
geons to minimize the risk of local recurrence in lumpec-
tomy patients. Strategies related to this effort as a function
of margin control were the focus of two studies presented
at the San Antonio meeting. An Australian study pre-
sented by Leong et al. (4) looked at risk factors for local
recurrence in 542 node-negative patients who had been
treated with lumpectomy and radiation; median follow-
up was 5 years. This study revealed that a positive lumpec-
tomy margin was one of the most significant predictors of
local recurrence (12% compared to 3% for those patients
with negative margins). Lumpectomy patients who were
younger than age 35 years also had a relatively higher risk
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of local recurrence. Smitt et al. (5), in a California study
looking at the predictive value of positive margins in 535
patients with either stage I or II disease who underwent
breast-conserving surgery and with a median follow-up of
6 years, had remarkably similar results; local recurrences
occurred in 14% of margin-positive cases compared to
3% of the margin-negative cases, and women younger
than 50 years were at increased risk for in-breast relapse
(5). The value of margin control is therefore well estab-
lished; however, there is no universal definition for what
constitutes the optimal negative margin in a lumpectomy
case. The previously noted phase III studies of breast-
conserving therapy versus mastectomy are perfect examples
of the variation that exists. The NSABP defines a negative
margin as the absence of tumor cells at the inked surface
(1); the Italians generally had relatively wide margin
control, by routinely performing quadrantectomies for T1
tumors (2); and the American NCI study mandated grossly
complete tumorectomies only, with no requirement for
microscopically clear margins (3). Despite differences in
margin status, these studies all found survival equivalence
between the lumpectomy and mastectomy arms.
Unfortunately international studies indicate that breast-
conserving surgery is underutilized in the United States
compared to other countries, despite confirmation of its
safety in long-term reports. The Arimidex, Tamoxifen,
Alone or in Combination (ATAC) trial, which compared
the aromatase inhibitor anastrozole to tamoxifen in
postmenopausal patients with early stage disease from 21
countries, revealed that American participants had a
significantly higher rate of mastectomy (51%) compared
to participants from the United Kingdom (42%). These
findings were reported by Locker et al. at the SABCS. The
disparity in utilization of the breast-sparing approach can
be attributed to either patient or physician bias or both these
factors.
Breast-conserving surgery has been studied in two
other settings: ductal carcinoma in situ (DCIS) and in
elderly patients. At the SABCS Cutuli et al. (7) reported a
French study of more than 1600 patients with pure DCIS
who were treated with either mastectomy, lumpectomy,
or lumpectomy plus radiation therapy at a median follow-
up of 83 months. As expected, because of the very favo-
rable tumor biology associated with DCIS, the overall rate
of distant metastasis was approximately 1%, although
it was slightly lower in the mastectomy group. In the
patients who were treated with breast-conserving surgery
with or without radiation and who developed a local
recurrence, approximately 50% of the recurrences were
invasive cancer rather than DCIS.
Also at the SABCS, Truong et al. (8), from the British
Columbia Cancer Agency, reported their experience with
breast-conserving surgery in stage I and II breast cancer
patients between the ages of 50 and 89 years, with strati-
fication of results by age categories: 50–64, 65–74, and
74–89 years. They noted lower rates of utilization of
radiation therapy in the oldest patients, and this was associ-
ated with a negative impact on both local rates of disease
control and overall survival.
 
SENTINEL LYMPH NODE BIOPSY
 
A great deal of active research is under way in the area
of lymphatic mapping and sentinel node biopsy, and this
is reflected in the national meetings. Since the initial pub-
lications of studies on the use of sentinel lymph node (SLN)
biopsy with concomitant ALND for breast cancer appro-
ximately a decade ago, nearly 70 published trials involving
more than 8000 patients have appeared in the literature.
A meta-analysis of these studies reported by Kim et al. (9)
at the 2002 American Society of Clinical Oncology (ASCO)
meeting revealed an overall SLN identification rate of
more than 90%, and a false-negative rate of 8.4%. With
the most recent studies revealing consistently lower
false-negative rates as the learning curve is more widely
overcome, SLN biopsy has emerged as a very promising
means of minimizing the morbidity of axillary staging.
Two major controversies remain unsettled in the SLN
research arena: whether there is a subset of the sentinel node-
positive patients who might safely avoid the complete
ALND, and how to best integrate lymphatic mapping
into neoadjuvant chemotherapy protocols.
Currently the standard of care is that patients with a
positive SLN should have a complete level I / II ALND.
However, the NSABP B-04 trial (10) showed that axillary
relapse is a relatively rare event in patients who present
with clinically negative axilla, despite the fact that a
significant fraction will have occult nodal metastases.
Furthermore, the SLN is the isolated site of metastatic dis-
ease in the axilla in 30–50% of patients, and there are also
abundant data demonstrating that adjuvant chemother-
apy and radiation can contribute to the eradication of
residual micrometastatic disease in the axilla. The Amer-
ican College of Surgeons Oncology Group will address
this question in an ongoing phase III clinical trial. This
critical study will randomize patients with a positive SLN
to either undergo complete ALND or axillary observation
only, and it will therefore define the survival benefit of the









Until the completion of phase III data, one avenue of
research is to identify ways of predicting which patients
are most likely to have residual metastatic disease in the
non-SLNs left behind after a positive SLN biopsy. One such
effort has been led by investigators at Memorial Sloan-
Kettering Cancer Center, in a study reported at the 2003
Society of Surgical Oncology Meeting (11). This project
involved 702 patients with positive SLNs who underwent
complete lymph node dissection. The clinicopathologic
findings in these patients were used to develop an algo-
rithm for estimating the likelihood of finding positive
nonsentinel nodes; contributing factors included primary
tumor size and whether the sentinel node metastases
were detected by immunohistochemistry or by routine
hematoxylin-eosin staining, among several other factors.
Regarding the SLN and neoadjuvant chemotherapy
issue, it remains unknown whether chemotherapy will
have a uniform effect on all axillary nodal metastasis or if
it might actually alter lymphatic drainage patterns; either
scenario could have an adverse effect on the accuracy of
a SLN biopsy performed after delivery of neoadjuvant
chemotherapy. A substantial body of evidence does exist
showing that chemotherapy can eliminate some axillary
nodal metastasis. In the NSABP B-18 study (12), the effect of
chemotherapy on axillary metastases can be inferred from
the substantially higher rate of axillary node negativity in
patients treated with preoperative chemotherapy (59%)
compared to those treated postoperatively (43%). As
direct evidence of chemotherapy-induced sterilization
of axillary metastases, we also have data on patients who
were staged at presentation by axillary ultrasound accom-
panied by sonographically guided fine-needle aspiration
(FNA) of abnormal-appearing lymph nodes. Studies from
the M. D. Anderson Cancer Center (13,14) and from the
Institut Curie (15) demonstrated that in patients with
a positive axillary FNA who then received neoadjuvant
chemotherapy followed by complete ALND, 25–33% were
rendered completely node negative.
The question then turns to whether a SLN biopsy
performed after neoadjuvant chemotherapy will reliably
identify the completely node-negative patients, or whether
the effect of incomplete chemotherapy on axillary metas-
tases might increase the false-negative rate for the mapping
procedure. Mamounas et al. (16) presented the largest
analysis of this question to date at the 2003 ASCO meet-
ing, where they reported accuracy data for SLN biopsies
performed with concomitant ALND following neoadjuvant
chemotherapy in participants of the NSABP B-27 trial.
Surgical findings for 428 cases were studied, with an 85%
SLN identification rate and an 11% false-negative rate.
An alternative strategy would be to stage neoadjuvant
patients with a SLN biopsy performed prior to the delivery
of neoadjuvant chemotherapy. A German study reported
at the SABCS (17) evaluated 11 neoadjuvant chemother-
apy patients, 10 of whom had the SLN identified prior to
therapy; 6 of these patients had a positive sentinel node
and all 6 were completely node negative on subsequent
ALND. Sabel et al. (18), from the University of Michigan,
reported on 24 patients who were staged with SLN biopsy
prior to delivery of neoadjuvant chemotherapy; of the
10 patients who were node positive before chemotherapy
and who then underwent postchemotherapy ALND, 30%
were rendered node negative. Clearly the disadvantage
to the prechemotherapy SLN biopsy sequence is that some
of the prechemotherapy node-positive patients will be
committed to an “unnecessary” complete ALND following
chemotherapy, chemotherapy will eradicate some axillary
metastases, and in others metastases were limited to the




The efficacy of surgical (prophylactic mastectomy, pro-
phylactic oophorectomy) and medical (chemoprevention
with tamoxifen) strategies to reduce breast cancer risk
have been well documented, resulting in the increased
significance of maneuvers designed to identify and stratify
high-risk women. Ductal lavage is a minimally invasive pro-
cedure involving cannulation and lavage of fluid-yielding
nipple orifices, thereby yielding cytologically evaluable
specimens. The strength of ductal lavage as a risk assess-
ment adjunct is related to the ability to detect cellular aty-
pia, a feature associated with a three- to fivefold increased
risk for breast cancer. A multicenter study by Dooley et al.
(19) confirmed the value of ductal lavage (compared to
direct nipple aspirates) in detecting cellular atypia. Ductal
lavage continues to be rigorously evaluated in a number
of ongoing studies.
Investigators from George Washington University (20),
Rush–Presbyterian St. Luke’s Medical Center (21), and the
University of Florida Health Science Center (22) all reported
their institutional experience with ductal lavage, revealing
cytologically evaluable fluid in 70–80% of cases and
atypia in 5–24% of lavaged patients. Khan et al. (23) studied
the topographic relationship between a lavaged ductal
system and the location of a breast tumor in mastectomy
cases from Northwestern University; a quadrant-matched
correlation was found in approximately two-thirds of cases.
In another study evaluating ductal lavage in breast
cancer patients and reported at the 2003 Society of Surgical
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Oncology meeting (24), investigators at the University of
Oklahoma found an inverse relationship between the
likelihood of atypia on ductal lavage of the contralateral
breast and increasing size of the primary tumor. These
data are consistent with past findings from Page et al. (23)
demonstrating that most of the increase in breast cancer
risk associated with atypia is expressed in the first 5 years
after diagnosis, after which the risk appears to return to
baseline if tumorigenesis has not occurred. These patterns
suggest that in a subset of breasts there may be a gradually
evolving field effect of abnormal proliferative activity that
follows an exposure, and after reaching a maximum level,
there is a subsequent decline. If a cancer develops during
this interval, decreasing rates of atypia will be seen else-
where in mammary tissue as the index tumor continues to








 Twenty-year follow-up of
a randomized trial comparing total mastectomy, lumpectomy, and
lumpectomy plus radiation for the management of invasive breast
cancer. 
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up of a randomized study comparing breast conserving surgery with
radical mastectomy for early breast cancer. 
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 Effect of preoperative
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 Incidence and impact of
documented eradication of breast cancer axillary lymph node metastases
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Hunt KK. A prospective trial of preoperative chemotherapy in resectable









 Incidence and prognostic
significance of complete axillary downstaging after primary chemotherapy
in breast cancer patients with T1 to T3 tumors and cytologically proven
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